New drug duo aims to tackle Transplant-Related lymphoma
NCT ID NCT05786040
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether combining two antibody drugs, tafasitamab and rituximab, can effectively treat a type of lymphoma that sometimes occurs after an organ transplant. About 28 adults who have developed this condition will receive the drug combination. The main goal is to see how many patients achieve a complete remission of their cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tafasitamab and rituximab (monoclonal antibodies)
What this could lead to
If successful, this combination could offer a more effective first-line treatment for post-transplant lymphoma, potentially improving remission rates without increasing toxicity.
What could go wrong
This is a small, early-phase (Phase II) trial with only 28 participants, so results may not apply broadly. The drugs may cause side effects like infusion reactions or infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYMORPHIC POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huntsman Cancer Institute
RECRUITINGSalt Lake City, Utah, 84112, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Rutgers Cancer Institute of New Jersey
RECRUITINGNew Brunswick, New Jersey, 08903, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of North Carolina-Hillsborough Campus
RECRUITINGHillsborough, North Carolina, 27278, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••